. Author manuscript; available in PMC: 2024 Apr 1.

Published in final edited form as: J Surg Oncol. 2023 Feb 13;127(5):871–881. doi: 10.1002/jso.27205

Table 5.

Summary of wound complications occurring in patients randomized to receive pazopanib (Regimen A) versus no pazopanib (Regimen B)

	Regimen A (RT + chemotherapy + pazopanib)	Regimen B (RT + chemotherapy)	P-value
	(n=17)	(n=5)
Wound complication grade
Grade I	6 (35.29%)	0	0.3208^§
Grade II	3 (17.65%)	1 (20.00%)
Grade III (IIIa, IIIb, IIIx)	8 (47.06%)	4 (80.00%)

Time from surgery to wound complication occurred
Median (range)	38.00 (0–220)	14 (0–70)	0.6192^¥


Delay in treatment	14 (82.35%)	2 (40.00%)	0.1005^§

Removed from protocol therapy	0	0

RT = radiation therapy

^§

Fisher Exact test was conducted

^¥

Two-sample median test was conducted